333 related articles for article (PubMed ID: 37282950)
1. [Effect of diosgenin on mTOR/FASN/HIF-1α/VEGFA expression in rats with non-alcoholic fatty liver disease].
Yin GL; Liang HY; Liang PP; Feng YN; Chen SW; Liu XY; Pan WC; Zhang FX
Zhongguo Zhong Yao Za Zhi; 2023 Apr; 48(7):1760-1769. PubMed ID: 37282950
[TBL] [Abstract][Full Text] [Related]
2. [Diosgenin alleviates NAFLD induced by a high-fat diet in rats via mTOR/SREBP-1c/HSP60/MCAD/SCAD signaling pathway].
Chen SW; Yin GL; Song CY; Meng DC; Yu WF; Zhang X; Feng YN; Liang PP; Zhang FX
Zhongguo Zhong Yao Za Zhi; 2023 Oct; 48(19):5304-5314. PubMed ID: 38114120
[TBL] [Abstract][Full Text] [Related]
3. Effects of moxibustion with wheat-grain size cone at "Zusanli" (ST 36) on vascular injury and oxidative stress in high-fat diet rats through mTOR/HIF-1α/VEGF signaling pathway.
Xu Q; Liu L; Zhang R; Yu Z; Hao F; Zhang J
Zhongguo Zhen Jiu; 2024 Apr; 44(4):433-440. PubMed ID: 38621731
[TBL] [Abstract][Full Text] [Related]
4. [Zuogui Jiangtang Qinggan Formula improves glucolipid metabolism in type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease by regulating FoxO1/MTP/APOB signaling pathway].
Xiang YX; Huang YL; Zhou M; Zou JJ; Liu X; Liu ZY; Xiao F; Yu R; Xiang Q
Zhongguo Zhong Yao Za Zhi; 2023 Aug; 48(16):4438-4445. PubMed ID: 37802870
[TBL] [Abstract][Full Text] [Related]
5. [Gynostemma pentaphyllum saponins alleviate non-alcoholic fatty liver disease in rats by regulating intestinal flora and short-chain fatty acid metabolism].
Zhong FW; Li GX; Zeng L
Zhongguo Zhong Yao Za Zhi; 2022 May; 47(9):2500-2508. PubMed ID: 35531697
[TBL] [Abstract][Full Text] [Related]
6. Effect of Dangfei Liganning capsule on liver X receptor α/steroid regulatory element binding protein-1/fatty acid synthase signal pathway in rats with metabolic- associated fatty liver disease.
Xiaoling LI; Fengxia S; Zimeng S; Yingxue Z; Jie LI; Qiuxiang Z
J Tradit Chin Med; 2022 Dec; 42(6):940-947. PubMed ID: 36378052
[TBL] [Abstract][Full Text] [Related]
7. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.
Yang JM; Sun Y; Wang M; Zhang XL; Zhang SJ; Gao YS; Chen L; Wu MY; Zhou L; Zhou YM; Wang Y; Zheng FJ; Li YH
World J Gastroenterol; 2019 Sep; 25(34):5105-5119. PubMed ID: 31558860
[TBL] [Abstract][Full Text] [Related]
8. [Lipid-lowering effect of drug pair Scutellariae Radix-Coptidis Rhizoma based on lipomics].
Liu WZ; Qian XJ; Zhang JQ; Liang K; Hu C; Wang XH
Zhongguo Zhong Yao Za Zhi; 2023 Dec; 48(24):6711-6720. PubMed ID: 38212031
[TBL] [Abstract][Full Text] [Related]
9. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
Zhang J; Du H; Shen M; Zhao Z; Ye X
J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
[TBL] [Abstract][Full Text] [Related]
10. [Effect of Fuzi Lizhong decoction in reducing liver injury of rats with non-alcoholic fatty liver via activating AMPK and suppressing NF-κBp65 pathway].
Yang JY; Shi ZH; Ma W; Tao DQ; Liu S; Chen L; Zhou XL
Zhongguo Zhong Yao Za Zhi; 2018 Aug; 43(15):3176-3183. PubMed ID: 30200715
[TBL] [Abstract][Full Text] [Related]
11. [Intervention of Catalpol on High-fat Diet Induced Nonalcoholic Fatty Liver Disease in Mice].
Tian X; Xiong Q; Chen L; Wen JR; Ru Q
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Dec; 41(6):746-755. PubMed ID: 31907123
[No Abstract] [Full Text] [Related]
12. [Difference of lipid-lowering efficacy of "Xinjianqu" before and after fermentation and its mechanism based on LKB1-AMPK pathway and 16S rDNA sequencing technology].
Li DH; Wang RS; Zhang ZL; Zhu JG; Sun MM; Qiao J
Zhongguo Zhong Yao Za Zhi; 2023 Apr; 48(8):2146-2159. PubMed ID: 37282903
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
Zhang DM; Zhang GY; Wang T; Zhong HJ; Chen WK
Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1279-83. PubMed ID: 16796890
[TBL] [Abstract][Full Text] [Related]
14. [Effects of lycopene on metabolism of glycolipid and inflammation in non-alcoholic fatty liver disease rats].
Zhang P; Li J; Li M; Sui Y; Zhou Y; Sun Y
Wei Sheng Yan Jiu; 2020 Mar; 49(2):254-271. PubMed ID: 32290942
[TBL] [Abstract][Full Text] [Related]
15. Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway.
Wang L; Jia Z; Wang B; Zhang B
Turk J Gastroenterol; 2020 Dec; 31(12):902-909. PubMed ID: 33626003
[TBL] [Abstract][Full Text] [Related]
16. [Effect of Nrf2 and related factors on the progression of nonalcoholic steatohepatitis].
Cai YQ; Zhang LZ; Wang DJ; Chen FM; Chen ZY; Zhu KY; Li JS; Yan MX
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2014 Sep; 30(5):465-70. PubMed ID: 25571645
[TBL] [Abstract][Full Text] [Related]
17. Sodium butyrate ameliorates non-alcoholic fatty liver disease by upregulating miR-150 to suppress CXCR4 expression.
Zhang N; Qu Y; Qin B
Clin Exp Pharmacol Physiol; 2021 Aug; 48(8):1125-1136. PubMed ID: 33721354
[TBL] [Abstract][Full Text] [Related]
18. [Effect of Erchen Decoction on liver mitochondrial function by inhibiting mTORC1/SREBP1/CAV1 pathway in mice with high-fat diet].
Ding SS; Zhuang Y; Liao Y; Kang J; Zhang LY; Shen JY; Liao LH
Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(3):763-769. PubMed ID: 38621880
[TBL] [Abstract][Full Text] [Related]
19. Purendan alleviates non-alcoholic fatty liver disease in aged type 2 diabetic rats via regulating mTOR/S6K1/SREBP-1c signaling pathway.
Fan L; Niu H; Zhao L; Yao R; He X; Lu B; Pang Z
Biomed Pharmacother; 2022 Apr; 148():112697. PubMed ID: 35176709
[TBL] [Abstract][Full Text] [Related]
20. [Effect of targeted inhibition of hypoxia-inducible factor-1α by 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole on the progression of non-alcoholic fatty liver disease in rats].
Shen WD; Zhang W; Xu QH; Liu PF
Zhonghua Gan Zang Bing Za Zhi; 2016 Oct; 24(10):749-754. PubMed ID: 27938560
[No Abstract] [Full Text] [Related]
[Next] [New Search]
